Combination treatment for advanced colorectal cancer with liver spread
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (retlirafusp alfa) combined with two chemotherapy drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has spread to the liver and has a specific gene change (RAS mutation). It aims to see if this combination can shrink tumors and improve outcomes in people who have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to the liver and can't be removed with surgery.
- Your cancer has a RAS gene mutation and is MSS (microsatellite stable) or pMMR (mismatch repair proficient).
- You have not received any previous treatment for advanced cancer.
- You are physically active and able to care for yourself (ECOG score 0-1).
- Your blood counts and organ functions are within normal limits.
- You have at least one measurable liver tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus another drug (Bevacizumab) and chemotherapy (CAPEOX) for people with colorectal cancer that has spread to the liver. The goal is to shrink the tumors enough to allow surgery to remove them.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
This trial tests a new combination of treatments for advanced colorectal cancer that has spread to the liver. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.